Nephros, Inc.
Nephros, Inc. (Nasdaq: NEPH) develops and markets point-of-use water filtration products for medical and commercial applications. Its medical portfolio includes microfilters and ultrafilters for infection control in healthcare facilities, and ultrafilters that purify water and bicarbonate concentrate used in dialysis… From the company’s description.
Over the twelve months to Sep 30, 2026, Nephros, Inc. reported revenue of $21.58M, up 20.4% from a year earlier, and net income of $1.91M. Its operating margin was 8.5%, and operations used $0.91M in cash. In fiscal 2025, it reported revenue of $18.79M, up 32.7% from fiscal 2024, and net income of $1.19M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nephros, Inc. does
In the company’s own words
Nephros, Inc. (Nasdaq: NEPH) develops and markets point-of-use water filtration products for medical and commercial applications. Its medical portfolio includes microfilters and ultrafilters for infection control in healthcare facilities, and ultrafilters that purify water and bicarbonate concentrate used in dialysis treatment; its FDA 510(k)-cleared Class II medical devices retain bacteria, viruses and endotoxins. Commercial products address taste, odor, scale, particulates, lead, cysts and Total PFAS, serving foodservice and hospitality venues as well as healthcare, industrial, laboratory, aviation and government customers. Nephros sells through distributors and value-added resellers, alongside direct sales, and reports its business through infection control, dialysis water and commercial filtration product lines. Products include the HydraGuard, NanoGuard, EndoPur and OLpūr lines. The company relies on third-party manufacturing for medical filters and produces some commercial filters itself. In 2025, it had 36 full-time employees, and three customers accounted for 44% of revenue. Its website is www.nephros.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- SOUTH ORANGE, NJ
- Fiscal year end
- December
- CIK
- 1196298
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nephros, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nephros, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nephros, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nephros, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nephros, Inc.'s last four quarterly filings that the numbers alone won't show?”